Navigation Links
Calibr and JDRF Partner to Support Diabetes Translational Research
Date:3/25/2013

LA JOLLA, Calif., March 25, 2013 /PRNewswire-USNewswire/ -- The California Institute for Biomedical Research (Calibr) and JDRF announced a partnership today to apply Calibr's drug discovery expertise to type 1 diabetes research projects in collaboration with academic investigators from JDRF's network. Termed the Translational Academic Research Partnership, the jointly funded Calibr-JDRF program will establish collaborative projects focused on promising type 1 diabetes therapeutic targets and the discovery of early drug leads for validation and follow-on development.  The initial collaborative projects will be seeded by leading academic investigators working in the area of beta cell biology. Calibr's Matt Tremblay explained the rationale, "The idea is to team up Calibr's chemical and high-throughput screening technologies with the beta cell experts from JDRF's network to validate targets and create new drug discovery programs in areas of novel biology."  The first year of the program will focus on promoting survival of pancreatic beta cells as an approach to restoring blood glucose control in type 1 diabetic patients.

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D.

As the largest charitable supporter of T1D research, JDRF is currently sponsoring $530 million in scientific research in 17 countries. In 2012 alone, JDRF provided more than $110 million to T1D research. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness.

For more information, please visit www.jdrf.org.   

About Calibr: The California Institute for Biomedical Research (Calibr) is an independent, not-for-profit organization established to accelerate the translation of basic biomedical research to innovative new medicines. The Institute partners with academic scientists around the world to translate research discoveries and new technologies into innovative new therapies for unmet medical needs. Calibr is led by Peter G. Schultz , Ph.D., a world-renowned chemist, biotechnology entrepreneur and Professor of Chemistry at The Scripps Research Institute in San Diego, CA. Located in San Diego, Calibr is housed in newly built labs located near The Scripps Research Institute, The Salk Institute for Biological Studies, the University of California, San Diego and Sanford-Burnham Medical Research Institute.

Contact:
The California Institute for Biomedical Research (Calibr)
Amit Bhatia
VP of Finance & Operations
T: +1-858-242-1000
F: +1-858-242-1001 
abhatia@calibr.org


'/>"/>
SOURCE The California Institute for Biomedical Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Fluke Calibration 9190A Ultra-Cool Field Metrology Well delivers best-in-class stability
2. Masy Systems Now NVLAP Accredited To Perform RH Calibrations
3. NSG Precision Has Perfected the Wavelength Accuracy Calibration Standard
4. NSG Precision Cells’ WAV-7 Didymium Standard Makes Calibrating Wavelength Accuracy a Snap
5. The WAV-1 UV/VIS Holmium Oxide Calibration Standard by NSG Precision Stands Alone Above the Competition
6. NSG Precision Leads Industry with Solid-State Nano-Deposition Calibration Standards
7. RoviSys Partners with POMS MES to Expand Life Sciences Capabilities
8. TaxOps Announces Partner Appointment to Prominent International Position with Fortune 100 Company
9. NineSigma Announces Winners in $25,000 Sustainable Packaging Challenge in Conjunction With Scientists Without Borders and Partners
10. Accelrys Announces Strategic Partnership with USDM
11. MedCity News and UBM Medica US Partner in Distribution of Health IT News
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , Feb. 20, 2017  Atrius Health and ... entered into an agreement to develop a cloud ... By providing a holistic view of the multiple ... Watson Cognitive Insights could be designed to support ... Health is an innovative nonprofit healthcare organization with ...
(Date:2/18/2017)... Feb 17, 2017 Research and Markets has ... Report" report to their offering. ... The report provides separate comprehensive analytics for ... , and Rest of World. Annual estimates and forecasts are provided ... is provided for these markets. Market data and analytics are derived ...
(Date:2/17/2017)...  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today presented ... drug candidates, PTG-100 and PTG-200, at the 12 ... Colitis Organization (ECCO).  The ECCO congress is being ... from February 15 – 18, 2017. ... drug candidates PTG-100 and PTG-200. PTG-100, a potential ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
Breaking Biology Technology:
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):